Showing 1,541 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

PrEP policies & guidelines

Gilead’s Regulatory Delays Block Access to Lenacapavir for PrEP

Editor's pick
Health GAP (Global Access Project)
4 August 2025
Pharmaceutical industry

Africa’s push for HIV independence advances with first procurement of locally made medicines

Editor's pick
UN News
4 August 2025
Injectable & long-acting PrEP

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

Editor's pick
Merck press release
16 July 2025
Injectable & long-acting HIV treatment

ViiV Healthcare and Medicines Patent Pool extend voluntary licensing agreement to enable access to long-acting injectable HIV treatment

Editor's pick
Medicines Patent Pool
15 July 2025
Pharmaceutical industry

HIV drugmaker Theratechnologies agrees to $254M buyout by CDMO Future Pak

Editor's pick
FiercePharma
10 July 2025
Injectable & long-acting PrEP

Global Fund Secures Access to Breakthrough HIV Prevention Drug Lenacapavir for Low- and Middle-Income Countries

Editor's pick
Global Fund News Releases
10 July 2025
Injectable & long-acting PrEP

Gilead to provide HIV prevention drug to 2 million people in lower-income countries at cost

Editor's pick
STAT (requires free registration)
10 July 2025
Pharmaceutical industry

CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacle

Editor's pick
FierceBiotech
7 July 2025
Pharmaceutical industry

Gilead’s Voluntary License on Lenacapavir: Key Limitations of the License and Recommendations to Improve Access

Editor's pick
Médecins Sans Frontières
7 July 2025
Injectable & long-acting PrEP

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Editor's pick
Gilead Sciences press release
19 June 2025
Pharmaceutical industry

FDA approves twice-yearly shot of Gilead drug for HIV prevention

Editor's pick
BioPharma Dive
19 June 2025
Injectable & long-acting PrEP

‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers

Editor's pick
The Guardian
17 June 2025
Injectable & long-acting PrEP

Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty

Editor's pick
Reuters
2 June 2025
Pharmaceutical industry

Gilead, 'closely attuned to' potential US policy shifts, stands by long-acting PrEP launch

Editor's pick
FiercePharma
28 April 2025
People with limited treatment options

Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years

Editor's pick
i-Base
22 April 2025
Access to healthcare

Manufacturer’s plans for equitable access to twice-yearly PrEP under fire

News
10 April 2025
Pharmaceutical industry

Johnson & Johnson Unit Ordered to Pay $1.64 Billion in HIV Drug Marketing Case

Editor's pick
Medscape (requires free registration)
1 April 2025
Pharmaceutical industry

Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts

Editor's pick
FiercePharma
27 March 2025
Pharmaceutical industry

After Gilead and J&J lawsuits, distributor Safe Chain sees its owners charged in criminal indictment

Editor's pick
FiercePharma
5 July 2024
Access to healthcare

‘Inward, Technocratic’ MSF Leadership Under Global Pressure to Reverse Decision to Close Access Campaign

Editor's pick
Health Policy Watch
26 June 2024
Injectable & long-acting PrEP

No HIV infections seen in groundbreaking trial of twice-yearly injectable PrEP

News
22 June 2024
Injectable & long-acting PrEP

Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention

Editor's pick
Gilead Sciences press release
21 June 2024
Pharmaceutical industry

Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention

Editor's pick
FiercePharma
21 June 2024
Injectable & long-acting PrEP

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions

Editor's pick
Treatment Action Group
21 June 2024